A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
Conclusion Although SB939 was tolerable at the dose/schedule given, and showed declines in CTC in the majority of evaluable patients, it did not show sufficient activity based on PSA RR to warrant further study as a single agent in unselected patients with CRPC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Heart Attack | Investigational New Drugs | Oral Cancer | Prostate Cancer | Study